Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

USA - NASDAQ:IOVA - US4622601007 - Common Stock

2.27 USD
-0.15 (-6.2%)
Last: 9/12/2025, 8:00:02 PM
2.3195 USD
+0.05 (+2.18%)
After Hours: 9/12/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, IOVA scores 3 out of 10 in our fundamental rating. IOVA was compared to 542 industry peers in the Biotechnology industry. The financial health of IOVA is average, but there are quite some concerns on its profitability. IOVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IOVA has reported negative net income.
In the past year IOVA has reported a negative cash flow from operations.
In the past 5 years IOVA always reported negative net income.
In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

IOVA has a Return On Assets (-42.97%) which is comparable to the rest of the industry.
The Return On Equity of IOVA (-55.82%) is better than 63.65% of its industry peers.
Industry RankSector Rank
ROA -42.97%
ROE -55.82%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IOVA's Gross Margin of 20.60% is fine compared to the rest of the industry. IOVA outperforms 72.14% of its industry peers.
IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IOVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IOVA has more shares outstanding
Compared to 1 year ago, IOVA has an improved debt to assets ratio.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IOVA has an Altman-Z score of -2.48. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IOVA (-2.48) is comparable to the rest of the industry.
There is no outstanding debt for IOVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.48
ROIC/WACCN/A
WACC9.61%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.27 indicates that IOVA has no problem at all paying its short term obligations.
The Current ratio of IOVA (3.27) is worse than 60.52% of its industry peers.
IOVA has a Quick Ratio of 2.89. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
IOVA's Quick ratio of 2.89 is on the low side compared to the rest of the industry. IOVA is outperformed by 62.73% of its industry peers.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 2.89
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.35% over the past year.
IOVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 636.96%.
EPS 1Y (TTM)26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
Revenue 1Y (TTM)636.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.73%

3.2 Future

IOVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.94% yearly.
IOVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.14% yearly.
EPS Next Y12.48%
EPS Next 2Y22.37%
EPS Next 3Y23.41%
EPS Next 5Y19.94%
Revenue Next Year66.21%
Revenue Next 2Y61.35%
Revenue Next 3Y55.28%
Revenue Next 5Y45.14%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IOVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

IOVA's earnings are expected to grow with 23.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.37%
EPS Next 3Y23.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IOVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (9/12/2025, 8:00:02 PM)

After market: 2.3195 +0.05 (+2.18%)

2.27

-0.15 (-6.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners69.56%
Inst Owner Change-8.72%
Ins Owners0.37%
Ins Owner Change8.52%
Market Cap821.40M
Analysts75.56
Price Target9.28 (308.81%)
Short Float %21.52%
Short Ratio3.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.58%
Min EPS beat(2)-47.45%
Max EPS beat(2)-13.7%
EPS beat(4)2
Avg EPS beat(4)-12.08%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.26%
EPS beat(8)5
Avg EPS beat(8)-5.2%
EPS beat(12)9
Avg EPS beat(12)3.29%
EPS beat(16)10
Avg EPS beat(16)2.22%
Revenue beat(2)0
Avg Revenue beat(2)-28.3%
Min Revenue beat(2)-40.82%
Max Revenue beat(2)-15.78%
Revenue beat(4)1
Avg Revenue beat(4)-12.53%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)6.69%
Revenue beat(8)2
Avg Revenue beat(8)-30.92%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9%
PT rev (3m)-15.57%
EPS NQ rev (1m)-0.49%
EPS NQ rev (3m)7.34%
EPS NY rev (1m)1.52%
EPS NY rev (3m)-7.64%
Revenue NQ rev (1m)-1.66%
Revenue NQ rev (3m)-8.48%
Revenue NY rev (1m)-9.9%
Revenue NY rev (3m)-9.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.4
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 2.04
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0.67
BVpS1.93
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.97%
ROE -55.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.6%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.84%
Cap/Sales 8.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.27
Quick Ratio 2.89
Altman-Z -2.48
F-Score5
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)104.04%
Cap/Depr(5y)1124.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
EPS Next Y12.48%
EPS Next 2Y22.37%
EPS Next 3Y23.41%
EPS Next 5Y19.94%
Revenue 1Y (TTM)636.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.73%
Revenue Next Year66.21%
Revenue Next 2Y61.35%
Revenue Next 3Y55.28%
Revenue Next 5Y45.14%
EBIT growth 1Y12.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.84%
EBIT Next 3Y15.56%
EBIT Next 5YN/A
FCF growth 1Y8.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.45%
OCF growth 3YN/A
OCF growth 5YN/A